← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Danaher DHR $158B	970	+31	+3%	$46.5B
2	2 Thermo Fisher Scientific TMO $249B	965	+4	+0.4%	$48B
3	3 Novartis NVS $279B	940	+21	+2%	$23.1B
4	4 Illumina ILMN $41B	561	+29	+5%	$25.2B
5	5 Agilent Technologies A $49.1B	539	-26	-5%	$11.7B
6	6 Regeneron Pharmaceuticals REGN $80.1B	509	-3	-0.6%	$32.9B
7	7 Ionis Pharmaceuticals IONS $7.1B	339	+54	+19%	$6.46B
8	8 Revvity RVTY $17B	315	-16	-5%	$5.43B
9	9 Charles River Laboratories CRL $14.4B	259	+7	+3%	$3.71B
10	10 Myriad Genetics MYGN $397M	252	-21	-8%	$3.31B
11	11 Alnylam Pharmaceuticals ALNY $30B	238	+22	+10%	$6.73B
12	12 DELISTED bluebird bio BLUE	210	+41	+24%	$3.81B
13	13 DELISTED SANGAMO THERAPEUTICS INC SGMO	171	+13	+8%	$827M
14	14 Bruker BRKR $8.47B	168	-3	-2%	$2.19B
15	15 PTC Therapeutics PTCT $4.98B	157	+25	+19%	$1.92B
16	16 Precigen PGEN $2.64B	154	+46	+43%	$4.29B
17	17 Azenta AZTA $1.63B	131	-18	-12%	$741M
18	ISEE 18 DELISTED IVERIC bio, Inc. Common Stock ISEE	129	+13	+11%	$1.4B
19	19 Ultragenyx Pharmaceutical RARE $1.47B	126	+26	+26%	$1.96B
20	20 DELISTED CATALENT, INC. CTLT	118	+24	+26%	$3.72B
21	21 Sarepta Therapeutics SRPT $1.78B	114	-6	-5%	$321M
22	22 DELISTED Adverum Biotechnologies ADVM	113	+29	+35%	$644M
23	23 Standard BioTools LAB $248M	104	+4	+4%	$1.29B
24	24 Pacific Biosciences PACB $619M	94	-7	-7%	$230M
25	25 Arrowhead Research ARWR $8.25B	88	-12	-12%	$212M